1
Return

Novel investigational therapeutics for generalized anxiety disorder (GAD)

delete2019-10-28
delete10
PRE
AI
B
Bella Schanzer
A
Ana María Rivas-Grajales
A
A. Khan
S
Sanjay J. Mathew *
DOI:10.1080/13543784.2019.1680638delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Introduction: Generalized anxiety disorder (GAD) is a common and disabling psychiatric condition that affects 3% of the population and exacts significant costs to society if untreated. There are numerous treatment options available, but all have side effects, and none are reliably effective; hence, there is a significant need for new medications. Areas covered: The authors reviewed clinical Phase II and III studies listed on the clinicaltrials.gov and clinicaltrialsregister.eu websites, 2007-present. Additional information was gathered from the study sponsor websites and Pubmed. The categories of mechanisms investigated include: modulators of GABAergic or glutamatergic activity; modulators of monoaminergic systems including serotonin, norepinephrine, and dopamine; and modulators of neuropeptide corticotropin release factor. Expert opinion: There are few investigational drugs in the later stages of clinical development. Challenges include high placebo response rates, enrollment of symptomatic volunteers with minimal depressive and anxiety comorbidity, and the lack of a unifying pathophysiological model. Drug developers should consider implementing trial designs such as sequential parallel comparison design to enhance signal detection. Inclusion of depressive comorbidity may also enhance signal detection by reducing placebo-responsivity. More studies examining glutamate-mediated neuroplasticity in GAD are needed.
Keywords:
Generalized anxiety disorder
novel therapies
clinical trials
non-benzodiazepine anxiolytics
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

E
Expert Opinion on Investigational Drugs
IF:
4.1
Papers:
3.4K
Citations:
5.7K

Organization

B
Baylor College of Medicine
Scholars:
4.1W
Papers: 3.0W
Citations: 4.2W
Cited Papers

Cited Papers

Citing Papers

Citing Papers